Abstract The purpose of this study was to compare the efficacy of intravitreal aflibercept versus ranibizumab for treating therapy-resistant diabetic macular oedema (DME). A 69-year-old man presented with persistent bilateral DME despite previous ranibizumab treatment. Bilateral study treatment comprised one cycle of three monthly ranibizumab injections (0.5 mg), followed by one cycle of three aflibercept injections (2.0 mg), a second ranibizumab cycle and a second aflibercept cycle. Baseline visual acuity (ETDRS score) was 60 letters for the right eye and 65 letters for the left eye. Baseline central foveal thickness (CFT) was 305 μm for the right eye and 453 μm for the left eye. Substantially improved outcomes were observed during the first aflibercept cycle. CFT was reduced by 150 μm (mean) in both the eyes and decreased below the lowest level achieved during the previous 2.5-year ranibizumab treatment. Visual acuity was improved by 17.5 letters (mean) in both the eyes. Reintroduction of ranibizumab immediately worsened the status of both eyes back to the baseline level. During the final aflibercept cycle, visual acuity and CFT improved to the same levels achieved during the first aflibercept cycle. In this case study, we prospectively switched the treatment three times and observed a dramatic and consistent treatment advantage for aflibercept.
aflibercept         0.9999999999993179^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Aflibercept           

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

μm                            0.9999999907530537^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

DME                           0.9181223599377125^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Distance_measuring_equipment

visual acuity                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Visual_acuity         

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

aflibercept                   0.9999999999993179^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Aflibercept           

aflibercept                   0.9999999999993179^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Aflibercept           

aflibercept                   0.9999999999993179^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Aflibercept           

diabetic                      0.9999999999726015^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Diabetes_mellitus     

CFT                           0.7906295256421169^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/WIN_35428             

CFT                           0.7906295256421169^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/WIN_35428             

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

Visual acuity                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Visual_acuity         

aflibercept                   0.9999999999993179^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Aflibercept           

oedema                        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Edema                 

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

aflibercept                   0.9999999999993179^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Aflibercept           

DME                           0.9181223599377125^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Distance_measuring_equipment

aflibercept                   0.9999999999993179^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Aflibercept           

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

visual acuity                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Visual_acuity         

macular                       0.9999610438872599^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Macula_of_retina      

foveal                        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Fovea_centralis       

CFT                           0.7906295256421169^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/WIN_35428             

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

μm                            0.9999999907530537^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

μm                            0.9999999907530537^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Micrometre            

intravitreal                  0.9999999999998863^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Intravitreal_administration

